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Chapter I 
Abstract 
Metallocene catalysis is an important division of polymerization chemistry. The 
design of appropriate ligands for metallocene catalysts has focused on stereochemical 
control and structural diversity. The synthesis of the potential ligand 2-(1-indenyl)-
phenol has been developed. Indenyl phenol ligands offer advancements over 
cyclopentadienyl ligands because the steric and electronic properties of the catalyst could 
be tailored to suit individual polymerization reactions. 2-(1-Indenyl)-phenol was 
synthesized with an overall yield of 4% and characterized with 1H NMR and 13C NMR. 
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Chapter I: Section I 
Introduction 
Advancements and developments in polymer chemistry have supplied the world 
with a variety of household and industrial products. Many common products, from 
dishwasher-safe food containers to indoor-outdoor carpeting, are realized through the 
advancement of polymer chemistry, specifically polymerization catalysis. 
Early research in the polymerization of basic monomers concluded that the 
physical properties of a polyolefin were strongly influenced by stereochemistry. Polymer 
stereochemistry can be atactic, isotactic, or syndiotactic. Atactic polymers are 
characterized by a random pattern of stereocenters alternating between R-configurations 
and S-configurations. Isotactic polymers, however, have consistent stereochemistry 
throughout. Finally, syndiotactic polymers contain blocks of alternating stereochemistry 
(see Figure 1.1 ). The physical characteristics of polypropylene are often influenced by 
stereochemistry. For example, atactic polypropylene is amorphous and gummy, isotactic 
polypropylene is crystalline, and syndiotactic polypropylene is rubbery materials with the 
properties of a thermoplastic elastomer. 
Figure 1.1 Stereoisomers of Polypropylene 
Atactic 
lsotactic 
Sy ndiotactic 
2 
As demonstrated in the preceding example of polypropylene, the physical 
characteristics of a polymer are influenced by stereochemistry. Polymerization reactions 
are tailored to produce desired stereochemical arrangements, and this stereochemical 
selectivity is achieved through the employment of catalysts. Catalyst choice also 
influences the molecular weight, microstructure, and rheological characteristics of 
polymers. Catalysts even influence the productivity of polymerization reactions. 
Two widely used polymerization methods are Ziegler-Natta polymerization and 
metallocene catalysis polymerization1. Ziegler-Natta polymerization needs both a 
transition metal catalyst and a group III metal co-catalyst to affect polymerization, and 
the stereochemical arrangement of the polymer varies as the identity of the transition 
metal varies. For example, titanium and vanadium complexes are both commonly used 
in Ziegler-Natta polymerization. Titanium catalysis often yields isotactic polymers, and 
vanadium catalysis often yields syndiotactic polymers. Two of the most common 
catalyst/co-catalyst systems are Ti Ch with Al(C2H5)2Cl or TiC14 with Al(C2H5)3. 
Metallocene catalysis polymerization uses a metallocene to catalyze 
polymerization. By definition, a metallocene is a positively charged metal ion bound to 
one or more cyclic organic anions (usually cyclopentadienyl (Cp) anions), and the anions 
are often bridged to prevent free rotation (see Figure 1.2). When the transition metal has 
a charge exceeding positive two, labile ligands, such as chlorides, are used to balance the 
remaining charge. Metallocene catalysis requires an excess of methyl alumoxane 
(MAO). Made by the hydrolysis oftrimethyl aluminum (TMA), methyl alumoxane 
donates its methyl groups to replace the labile ligands on the metal center. When one of 
3 
those methyl groups leaves the metal center, the metal center is left with a positive charge 
which is partially balanced by an a-agostic association with a methyl hydrogen. (MAO 
serves as a non-coordinating anion to balance the positive metal center.) a-Agostic 
association, however, does not fully balance the positive charge on the metal center, 
leaving the metal center electrophilic (see Figure 1.2). 
Figure 1.2 Metallocene Catalysis: Part I 
~ 
Zr I --~ ,,,, CH2 = 
Cl <62C)> 
Example Catalyst 
With the metal center electrophilic, polymerization is ready to begin. When the 
alkene monomer is added, the II orbital of the alkene shares electrons with the empty d-
orbital on the metal center to balance the electrophilic metal. Next, the methyl group 
migrates from the metal to the methine carbon of the propylene through a series of 
electron shifts and a four-membered transition state (see Figure 1.3). 
Figure 1.3 Metallocene Catalysis: Part II 
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The metal center is again electrophilic, though sharing an a-agostic association 
with the propylene monomer. The addition of a second monomer can now occur, and the 
electrons once again shift and form the final product via a five-membered transition state 
(see Figure 1.4). 
Figure 1.4 Metallocene Catalysis: Part III 
e· shift 
..... 
As shown in Figure 1.4, when the anion ligands are bridged to prevent free -
rotation, isotactic polymers result. Approaching monomers must be aligned so that their 
large methyl group is pointed away from the bulky polypropylene group, otherwise the 
approaching monomers cannot get close enough to the metal center to form a complex. 
However, when the cyclopentadienyl ligands are not bridged to prevent free rotation, 
syndiotactic or atactic polymers result. 
In 1995, Coates and Waymouth2, motivated by the theory of oscillating 
stereocontrol, synthesized the unbridged metallocene bis(2-phenylindenyl)zirconium 
dichloride [(2-Phlnd)2ZrCh], 1. This unbridged metallocene freely rotates between the 
chiral rac-like form, which produces a block of isotactic polymer, and the achiral mesa-
like form, which produces a block of atactic polymer. Thus, the result is a syndiotactic 
polymer with alternating blocks of isotactic and atactic stereochemistry (see Figure 1.5). 
Further, Coates and Waymouth demonstrated that their polymerization catalyst could 
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produce a wide array of polymers, the elastomeric properties of which depended on the 
reaction conditions. 
isotactic 
block 
Figure 1.5 Rae- and Meso-like Isomers of (2-Phlnd)iZrP+ 
-~ ~-
rac-like isomer rreso-like isomer 
1 
atactic 
block 
Catalyst 1 was synthesized from the reaction of 2-phenylindenyllithium and ZrC14 
with 82% yield. 1H nuclear magnetic resonance (NMR) spectroscopy and X-ray 
crystallography both confirmed the presence of both the rac- and mesa-isomers. In the 
presence of MAO, 1 catalyzes propylene polymerization. In fact, the polymerization was 
sensitive to both monomer pressure and temperature. Increases in productivity and 
molecular weight resulted from increasing propylene pressure or decreasing the 
polymerization temperature. Thus, Coates and Waymouth not only synthesized a catalyst 
with oscillating stereocontrol, but they also profiled polymerization productivity and 
molecular weight as functions of propylene pressure and polymerization temperature. 
Another interesting study on metallocene polymerization catalysts came from 
McKnight, Masood, Waymouth, and Straus3, when they synthesized a series of mono-
cyclopentadienyl-amido (CpA) catalysts. These catalysts were unique in both their 
6 
ability to incorporate styrene in copolymerizations with ethylene and their stability at 
high polymerization temperatures (up to 160 °C). 
The catalysts, 2, 3, and 4 were prepared in low to moderate yields (5-50%) 
through either a metathesis route or amine elimination from Ti(NR2) 4, and produced high 
molecular weight atactic polypropylene polymers (see Figure 1.6). The incorporation of 
the amine into the ligand framework had no effect on stereochemical control. 
Figure 1.6 Mono-Cyclopentadienyl-Amido Catalysts 
Me2z /TiCl2 Me2z /T1Cl2 
Me2Si ZnCl2 
"/ N N N I I + R 
R 
2 3 4 
R= t-Butyl, CHMePh, or C 6H11 
From their various catalysts McKnight, Masood, Waymouth, and Straus learned 
that the structure of the cyclopentadienyl ligand had the most influence on the resultant 
polymer molecular weight and polymerization productivity. The identified trend was for 
the Me4C5-based catalysts to have higher molecular weight and productivities than the 
indenyl analogues. Thus, the incorporation of the amine was not a significant variable in 
stereochemical control, polymerization productivity, or resultant polymer molecular 
weight. 
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Another generation of polymerization control came from Chen, Fu, Stem, and 
Marks4 when they synthesized the ligand precursor 2-(tetramethylcyclopentadienyl)-4-
methylphenol ((TCP)H2)), 5 . The convenient, one-pot synthesis of 5 (48.6% yield), 
makes it an ideal ligand precursor. Further, the titanium (6) and zirconium (7) (TCP)H2 
complexes were also synthesized in a convenient one-pot reaction. Specific 
polymerization control is achieved through modifications of the aryl fragment, with up to 
four possible modification sites (see Figure 1. 7). 
Figure 1.7 (TCP)H2 in Titanium and Zirconium Complexes 
OH 
5 6 7 
The synthesis of this ligand precursor is important because it offers polymer 
research an important starting point. Modifications of 5 could tailor the steric and 
electronic properties of the catalyst to suit individual polymerization reactions. Ligand 5 
can accommodate up to four modifications. However, ifthe five-membered ring were 
replaced by an indenyl group, six modifications could be accommodated. 
Thom, Fanwick, Chesnut, and Rothwe115 synthesized a similar cyclopentadienyl 
ligand, 2-(indenyl)-4,6-di-tert-butyl phenol (8), and successfully coordinated it with 
8 
titanium, zirconium, and tantalum. When the ligand is coordinated with titanium in 
complexes 9 and 10, the hydroxyl oxygen was bound directly to the metal center (see 
Figure 1.8). Thus, it was demonstrated that indenyl phenols are viable precursors of 
metallocene complexes. 
Figure 1.8 Titanium Complexes of Rothwell Ligand 
I-Bu 
Cp~l'le 
~" 0 ""'- tie 
t-Bu 
I-Bu I-Bu I-Bu 
8 9 10 
Previous work on the synthesis of 2-indenylphenols also came from Kim.6 As 
outlined in Scheme 1.1, the Kim synthesis utilized a Grignard reaction to couple a 
methoxy aryl group with indanone (X =Br or I). Dehydration of the resulting alcohol in 
12, catalyzed with p-toluenesulfonic acid, then yielded ether 13. Demethylation of 13 
with aluminum bromide and ethanethiol yielded impure 2-(1-indenyl)-phenol (14).6 
9 
Scheme 1.1 Kim Synthesis of 2-( 1-Indenyl)-Phenol (14) 
1. AIBr3 
2. EtSH 
OH 
11 12 13 14 
Building on the work of Kim,6 the synthetic strategy for this research is outlined 
in Scheme 1.2. The protection of 2-bromophenol (15) with dihydropyran (DHP) should 
afford compound 17. When added to 17, n-butyllithium should form a carbanion which 
adds to 1-indanone. Hydrochloric acid and methanol should effect dehydration to yield 
compound 14. The potential advantage of this synthetic strategy over the Kim6 synthesis 
includes fewer steps as well as easier isolation and purification. 
Scheme 1.2 Proposed Synthesis of 2-(1-Indenyl)-Phenol (14) 
Q + Br 0 0 pyridinium p-toluene sultanate ice bath OCBr OTHP 
OH 
15 16 17 
0 
OC' oJ ~ n-Buli HCI .,:::::-~ I OTHP -78 °C CH30H 
OH 
17 14 
10 
Chapter I: Section II 
Results and Discussion 
A. Synthesis of tetrahydropyran-protected 2-bromophenol (17) 
Scheme 1.3 Synthesis of THP-Protected 2-Bromophenol (17) 
°' 
0 pyridinium p-toluene sulfonate ex Br + ice bath Br 0 OTHP 
OH 
15 16 17 
Scheme 1.3 shows the synthesis of tetrahydropyran-protected 2-bromophenol 
(17). The mole ratio of 15:16 was varied from 1: 10 to 1 :5 to determine the resulting 
effects on overall yield, and a 1 :5 mole ratio was found to give the best yield. The 
solvent was also varied to determine the optimal solvent, and it was determined that the 
optimal yield was obtained by omitting the reaction solvent7 (see Table 1). Optimal 
conditions were determined to be a 1 :5 mole ratio of 15:16 in the absence of solvent, 
which produced an 88.45% yield. The cited publication did not offer a percent yield for 
comparison. 
Table 1. Reaction Optimization for the Synthesis of THP-protected 2-Bromophenol 
Solvent 15:16 Mole Yield 
Ratio 
Benzene 1:10 No yield. 
Dichloromethane 1:10 83.00% 
Dichloromethane 1 :5 62.00% 
No solvent 1 :5 88.45% 
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The identity of 17 was confirmed by thin-layer chromatography (TLC) and 1H 
NMR. Since no 1H NMR data was provided by Foster et al. 7, proton assigmnent was 
completed to confirm the identity of compound 17. Three particularly important proton 
assigmnents were for the proton of the stereocenter (o = 5.50, t) and the two protons 
adjacent to the stereocenter (o = 3.89, d oft). Additionally, all four aromatic protons 
were assigned. The 1 H NMR spectrum can be found as Figure 3 .1 in the appendix. 
B. Synthesis of 2-(1-indenyl)-phenol (14) 
Scheme 1.4 Synthesis of 2-(1-Indenyl)-Phenol (14) 
0 (X'' oO ~ n-Buli HCI ,.,::::-~ I OTHP -78 °C CH30H 
OH 
17 14 
Scheme 1.4 shows the synthesis of 2-(1-indenyl)-phenol (14). Though the 
reaction was successful, the percent yield was very low. The crude product contained 
five different organic compounds: Rr in benzene= 0.68, 0.50, 0.45, 0.30, and 0.15. 1H 
NMR confirmed that 14 was the compound with an Rrvalue of0.50. Since the desired 
compound had an Rrvalue very close to one of the other products (Rr= 0.45), isolation 
was difficult. The crude products of three reactions were combined for purification 
because the yield of crude oil was very low for each reaction. Flash chromatography in 
benzene successfully isolated 14 from the crude oil, but with a total production of 
l .0728g, which corresponded to an overall percent yield of 4.0%. Compared to the Kim 
12 
synthesis,6 which only produced impure 2-(1-indenyl)-phenol, the yield of 4.0% is an 
improvement. 
Compound 14 was characterized using TLC, 1H NMR, and 13C NMR. Three 
important proton assignments were the phenol proton (o = 5.44, s), vinyl proton (o = 
6.68, t), and benzylic proton (o = 3.61, d). 13C NMR spectral data was also consistent 
with the structure represented in 14. The 1H NMR spectrum and 13C NMR spectrum can 
be found as Figures 3.2 and 3.3 in the appendix. 
13 
Chapter I: Section III 
Future Research 
Although this project successfully produced 2-(1-indenyl)phenol, further research 
is needed. Since the yield was low, reaction optimization is needed: 
1. The four side products present in the crude oil need to be identified. Leaming the 
identity of these side products would illuminate the side reactions occurring which reduce 
the ultimate yield. If these reactions could be identified, steps could be taken to reduce 
their occurrence. 
2. Other reaction components, such as solvent and mole ratio, should also be 
explored to determine effect on yield. 
3. The employment of alternate protecting groups may further refine the reaction 
and increase the yield. 
14 
Reagents 
Chapter I: Section IV 
Experimental 
2-Bromophenol (15, 98%), n-butyllithium (n-BuLi, 1.5 Min 
hexanes), 3,4-dihydro-2H-pyran (97%), 1-indanone (99+%), and pyridinium p-toluene 
sulfonate (98%) were purchased from Aldrich Chemical Co. and used as received. 
Tetrahydrofuran (THF) was obtained from Fisher Scientific and freshly distilled from 
calcium hydride. Benzene, anhydrous diethyl ether, ethyl acetate, methanol, and hexanes 
were obtained from Fisher Scientific and used without further purification. All water 
used was deionized. All flash chromatography was carried out on 200-400 mesh silica. 
Physical and Analytical Measurements All 1 H NMR spectra and 13C NMR 
spectra were obtained at 23 °C on a GE QE-300 MHz FT-NMR spectrometer, and the 
chemical shifts were reported relative to internal solvent reference values of 
deuterochloroform (CDCh) from Aldrich Chemical Co. (for 1H NMR; s, singlet; d, 
doublet; t, triplet; q, quartet; and m, multiplet). Thin-layer chromatography (TLC) was 
performed on Analtech uniplate silica gel chromatography plates using benzene or a 
solution of 9: 1 hexane/ethyl acetate as the eluent and visualized with ultraviolet light or 
iodine stain. 
Synthesis of tetrahydropyran-protected 2-brornophenol (17) At room 
temperature and atmospheric pressure, 2-bromophenol (10.6586 g, 61.433 mmol) was 
combined with dihydropyran (27.1516 g, 322.772 mmol) and the catalyst, pyridinium p-
toluene sulfonate (93.3 mg, 0.371 mmol). After stirring approximately 1.5 hours in an 
15 
ice bath, the mixture was combined with 30 mL of diethyl ether and 20 mL of distilled 
water in a large separatory funnel. Two layers separated, and the organic layer was 
isolated and washed twice with 1 M NaOH (10 mL) and dried over magnesium sulfate. 
Solvent was removed in vacuo. The oil product was isolated by flash chromatography in 
a solution of9:1 hexanes/ethyl acetate. Yield= 13.9111 g, 88.45 %. TLC: Rr= 0.56 in 
9:1 hexanes/ethyl acetate. 1H NMR (CDCh): 8 7.52 (d of d, J 3H-H = 3.76 Hz, J4H-H = 
1.46 Hz, lH, Ar-H ortho to oxygen), 7.22 (d oft, J 3H-H = 7.82 Hz, J4H-H = 1.39 Hz, lH, 
Ar-H para to 0), 7.13 (d of d, J3H-H =4.21 Hz, J4H-H = 1.64 Hz, lH, Ar-H ortho to Br), 
3 4 6.84 (d oft, J H-H = 7.52 Hz, J H-H = 1.55 Hz, lH, Ar-H para to Br), 5.50 (t, JH-H = 2.82 
Hz, lH, stereocenter), 3.89 (d oft, J3H-H = 11.13 Hz, J4H-H = 3.19 Hz, 2H, adjacent to 
stereocenter), 3.62-3.55 (m, 2H ), 2.17-1.70 (m, 4H). 
Synthesis of 2-(1-indenyl}-phenol (14) In an argon environment, 
tetrahydropyran-protected 2-bromophenol (15, 13.9111 g, 54.337 mmol) was dissolved in 
40 mL of THF and stirred at -78 °C. Next, n-BuLi (1.5 Min hexanes, 36.0 mL, 54.8 
mmol) was added over ten minutes, and the resulting solution stirred at -78 °C for thirty 
minutes. Next, 1-indanone (4.7546 g, 35.976 mmol) dissolved in 20 mL of THF was 
added over ten minutes, and the temperature control was removed. As the mixture 
warmed to room temperature it transformed into a white liquid with a suspended yellow 
precipitate. Overnight storage caused the mixture to tum from white to brown, and 20 
mL of distilled water was added as a quench. After transfer into a large separatory 
funnel, 100 mL of ethyl ether and 80 mL of water were added to the mixture. The 
aqueous layer was washed twice more with diethyl ether (35 mL each), and all of the 
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organic extracts were combined to fonn one solution. Brine and magnesium sulfate were 
used to remove water, and solvent removal was afforded through an air purge. 
The crude product was dissolved in 200 mL of methanol, and 25 mL of 
concentrated hydrochloric acid was added. Reflux conditions were then established and 
maintained for 30 minutes. The pH was adjusted to approximately 7 through the addition 
of 6M NaOH (aq) and 25 mL of saturated NaHC03(aq) was added to stabilize the pH of 
the reaction solution. After overnight storage, the solution was a clear, brownish-yellow 
liquid with two precipitates: a white precipitate and a dark purple precipitate. When an 
additional 25 mL of NaHC03(aq) was added, the amount of white precipitate increased. 
The mixture was combined with 175 mL of diethyl ether and 80 mL of water, and 
the resulting aqueous layer was then extracted twice more with diethyl ether (50 mL 
each). All of the organic layers were combined to form one solution, and a wash with 75 
mL of brine followed. Magnesium sulfate and air purge were used to remove excess 
water and solvent. The crude products from multiple reactions were combined to form 
one large product for purification. The final clear, brown oil was isolated through flash 
chromatography in benzene. Yield= 1.0738 g, overall yield 3.96%. TLC: Rr = 0.50 in 
benzene. 1H NMR (CDCIJ): 8 7.58 (d of d, J38 _H = 5.95 Hz, J4H-H = 2.53 Hz, lH, Ar-H 
ortho to OH), 7.41-7.29 (m, SH, Ar-H), 7.08-7.06 (m, 2H, Ar-H), 6.68 (t, JH-H = 2.03 Hz, 
lH, vinyl H), 5.44 (s, lH, OH), 3.61 (d, J8 _H = 2.26 Hz, 2H, benzylic H). 13C NMR 
(CDCh): o 153.06, 144.29, 143.74, 140.51, 132.85, 129.51, 129.31, 126.44, 125.52, 
124.09, 121.53, 120.59, 120.37, 115.64, 38.65. 
Chapter I: Section V 
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Chapter II 
Abstract 
A large percentage of breast malignancies overexpress the nuclear estrogen 
receptor (ER) protein. Binding to nuclear receptors is a mechanism for concentrating 
ligands in cells, and this pathway can be expanded to ligand analogues provided the 
analogue is still recognized by the receptor. Estradiol is a high-affinity ligand for the 
estrogen receptor, and 7a monosubstituted estradiol derivatives have also been shown to 
be high-affinity ligands for ER. Therefore an estradiol derivative with a cytotoxic moiety 
incorporated into a 7a substituent could selectively concentrate in breast malignancies to 
cause cell death. A generation of linkage molecules designed to incorporate a cytotoxic 
moiety into 7a substitutents of estradiol has been developed. Since bidentate carboxylate 
ligands are known to form highly stable complexes with platinum, malonate groups were 
chosen as the common element in this family of linkage molecules. Alkylating malonate 
groups with diiodoalkanes afforded CD-iodoalkyl(methyl) malonate esters. One specific 
ester, diisoamyl-6-iodohexyl(methyl) malonate, was used to alkylate the 7a position of an 
estradiol derivative. 
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Chapter II: Section I 
Introduction 
Cancer is the second leading cause of death in Americans. The Centers for 
Disease Control and Prevention (CDC) predict that in 2003 alone, over 500,000 
Americans will die of cancer1• Since 1990, over 17 million new cases of cancer have 
been diagnosed, and experts anticipate another 1.3 million cases to be diagnosed in 
2003 1. Breast cancer accounts for a full one third of all cancers diagnosed in women, and 
is the most prevalent type of cancer among American women. The National Cancer 
Institute (NCI) predicts that one in every eight women in the United States will have 
breast cancer sometime during her lifetime. Though breast cancer does occur in men, it 
is far more prevalent in women. 
McGuire, Horwitz, Pearson, and Segaloff2 found that a large percentage of breast 
malignancies contain elevated levels of the estrogen receptor (ER) protein. As a result, 
breast malignancies are characterized as ER-positive or ER-negative. The presence or 
absence of elevated ER levels dictates different therapeutic treatments. In its natural role, 
ER is a transcription factor and is considered a 'nuclear receptor' since it functions in the 
nucleus. Specific therapeutic agents have been developed to treat ER-positive 
malignancies. 
Tamoxifen, 1, (Z-1-[ 4-(2-dimethy laminoethoxy )phenyl ]-1,2-dipheny 1 but-1-ene) 
is a selective estrogen receptor modulator (SERM) currently used to treat hormone-
responsive breast cancer (see Figure 2.1). Marketed as Nolvadex®, tamoxifen has been 
shown to successfully treat these malignanices. Tamoxifen is known as a partial 
antiestrogen- it acts as both an agonist and an antagonist of ER-which poses two 
20 
major disadvantages. First, though approximately one half of ER positive malignancies 
initially respond to treatment with tamoxifen, a large percentage of the responding tumors 
eventually resume growth under the administration of tamixifen3. Second, tamoxifen has 
been found to cause proliferation of endometrial cells in the uterus, thus increasing the 
patients' risk of developing endometrial cancer4 . The action of this drug as both an 
agonist and an antagonist in the human body can be explained by the current model of 
selective estrogen receptor molulators (SERMs). 
Figure 2.1 Structure of Tamoxifen 
Originally considered uniform estrogen antagonists, SERMs actually display an 
unusual tissue-selective pharmacology in that they act as agonists, antagonists, and mixed 
agonists/antagonists4 . The action of SERMs is dictated by tissue localization. In the 
bone, liver, and cardiovascular system, SERMs are agonists, but in the brain and breast 
they act as antagonists. When localized in uterus tissues, SERMs act as mixed 
agonists/antagonists, causing the adverse side effects noted with tamoxifen. 
The pharmacology of estrogens is tripartite; third parties, such as coregulatory 
proteins and gene promoter elements, are required in addition to the ligand and estrogen 
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receptor. These third party molecules determine the action of estrogens in specific cells. 
For example, the presence of a coactivator known as SRC 1 in uterine cells is responsible 
for the agonism of tamioxifen in these cells. 
Katzenellenbogen and Katzenellenbogen5 also published important research 
which explored nuclear hormone receptors as ligand-activated transcription regulators. 
The nuclear receptor superfamily includes proteins that mediate steroid hormones and 
some non-steroidal hormones. Proteins are admitted into the nuclear receptor 
superfamily based on the presence of a six-domain structure outlined in Figure 2.2. 
Domain C, a small domain of only 70-80 amino acids, is responsible for DNA binding 
and is the most highly conserved region of the six-domain structure. Domain E, a large 
domain of approximately 250 amino acids, is responsible for hormone binding and 
dimerization and is also moderately conserved. Length and sequence conservation within 
the other four domains is poor across the superfamily of nuclear receptors. 
Figure 2.2 Domains of the Nuclear Receptor Superfamily 
A/B C D E F 
Estrogen Recptor 
----1111111111------------
100% 100% 
Glucocorticoid Receptor 
1111111111 
72% 56% 
Thyroid Hormone Receptor 
-1111111/ll 
54% 48% 
Retino1c Acid Receptor 
--1111111111 
64% 50% 
Common domain structures for four members of the nuclear receptor 
superfamily( all alpha, humanreceptors). Percent sequence similarity 
(relati1.e to estrogen receptor) are listed for Domains C and E. 
22 
Nuclear hormones are involved in transcriptional regulation. A simplified 
sequence of gene activation via nuclear receptors can be readily described; the hormonal 
ligand binds to its receptor, the newly-formed receptor-ligand complex binds to a 
hormone response element in the promoter region of a regulated gene, and transcription 
of the gene containing the promoter is activated5. Of course, this scheme does not 
consider important variations such as the cellular distribution of the receptor when the 
ligand is absent, receptor dimerization, and the complex interactions which can occur 
between nuclear receptors and DNA response elements5. The exact role 
of a nuclear receptor is a function of the cell in which it is acting and the gene whose 
activity is being modulated. 
Binding to nuclear receptors is a mechanism of concentrating ligands in cells. 
This pathway can be expanded to include the concentration of ligand analogues in cells, 
provided the analogue is still recognized by the nuclear receptor. The design of synthetic 
ligand analogues with high affinity for their correlating nuclear receptors requires 
knowledge of the shape of the ligand binding domain of the nuclear receptor. This 
important information can be used to predict what types of ligand modifications will be 
tolerated by the receptor without a substantial decrease in binding affinity. 
Tedesco, Katzenellenbogen, and Napolitano6 utilized 7a and 11 ~mono- and di-
substituted estrogen analogues to probe the shape of the estrogen receptor ligand binding 
domain (LBD). Estradiol derivatives with large, nonpolar substitutents at either the 7a 
(2) or 11 ~ (3) positions are known to be high affinity ligands for ER7 (see Figure 2.3 ). 
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Figure 2.3 High-affinity Ligands for the Estrogen Receptor 
OH 
HO HO 
1 2 
ER tolerated the large substituents of 2 and 3, even though each analogue had a 
very different molecular shape. The question that Tedesco, Katzenellenbogen, and 
Napolitano 6 investigated was whether ER bound 2 and 3 in the same pocket or if two 
separate binding sites were present. Without X-ray crystal structures of the ER ligand 
binding domain, it was not clear if ER bound the different estradiol analogues in separate 
binding cites or if rotating the molecules on a pseudo C2 axis allowed them into the same 
binding site regardless of their bulky substituents. 
The 'one-pocket model' proposed by Poupaert8a and von Angercr,8b is based on 
the fact that 7a and 11 P-monosubstituted estrogens display equivalent binding within the 
ER ligand binding domain. This model postulated approximate interconversion of the 7a 
and 11 p positions by rotation about a pseudo C2 axis through mono substituted estradiol 
analogues (see Figure 2.4). In contrast, the 'two-pocket model' proposed by Leclerq et 
al9 theorized that at least two ligand binding domains were present on ER, and that ligand 
placement in either binding domain operated as a function of substituent location. 
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Figure 2.4 Rotation of Estradiol About a Pseudo-C2 Axis 
normal orientation flipped orientation 
Tedesco, Katzenellenbogen, and Napolitano6 addressed these apparently 
conflicting theories by preparing 7a and 11 P-monosubstituted and disubstituted estradiols 
and measuring their binding affinity for ER. Unable to clearly validate either the 'one-
pocket model' or the 'two-pocket model, they proposed an alternate version of the 'two-
pocket model' with two important features: the pocket that accommodates the 1 lP-
substitutent is larger than the pocket that accommodates the 7a-substitutent, and the 
pockets are positioned so that the independent and additive contribution of multiple 
substituents breaks down before the energy contribution of an individual substituent 
becomes compromised. 6 
The tolerance of ER for large substituents at the 7a position suggests a drug 
delivery strategy. Since many breast cancer malignancies have elevated concentrations 
of ER2, one strategy is to link a cytotoxic moiety to a 7a monosubstituted estrogen 
derivative with high affinity and selectivity for the estrogen receptor. The resulting 
estrogen conjugate should concentrate in the nucleus of breast cancer malignancies 
through ER binding. One possible family of cytotoxic estrogen conjugates is based on 
platinum antitumor drugs. 
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Cisplatin (4) and carboplatin (5) are drugs commonly used to treat cancers of the 
testis, ovary, head, and neck (see Figure 2.5). The antitumor activity of these drugs 
comes from their ability to inhibit DNA replication. When platinum loses its 'leaving 
groups' (chloride or carboxylate), it bridges adjacent purine residues, 10 and the normal 
enzyme system responsible for DNA repair is unable to reverse the damage in susceptible 
tumor cells. 11 However, these drugs are also accompanied by detrimental side effects, 
namely nephrotoxicity. 
Figure 2.5 Structures of Cisplatin and Carboplatin 
Cisplatin Carboplatin 
H3N NH 3 
............. ......-
o/P~o 
0 0 
4 5 
The development of a platinum analogue that will selectively concentrate in 
malignant cells offers two advantages: less damage to healthy cells and smaller 
therapeutic doses. Both of these inherent advantages suggest that such an analogue could 
offer patients effective therapeutic treatment with a reduction in the adverse health effects 
common with chemotherapy. One option for realizing such a compound is conjugation 
of a platinum moiety to the 7a position of estradiol. The general structure of the target 
platinated estrogen (6) is given in Figure 2.6. As in cisplatin ( 4) and carboplatin (5), 
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ammonia is designed as the amine ligand. The estrogen is designed to be an ER 
antagonist that will serve as the 'leaving group' when 6 produces cross-linked DNA to 
induce the death of malignant cells. A malonate group was chosen for coordination to 
platinum because bidentate carboxylate ligands are known to form highly stable 
1 . h 1 . 12 comp exes wit p atmum. 
Figure 2.6 Structural Comparison of Proposed Therapeutic Agent with 
Clinically-Used Platinum Compounds 
Clinically Used Therapeutic Agents Proposed Therapeutic Agent 
r - - - - -- - - - - - ---- -- -- - - - --- -- --- - - --- - - -- - - - - -- - - - - -- -- -- --- -- -- -- -- - - - -- - , 
l amine 
.I ~--------~~--~~1--------~~--~f-i~-----------~--~~------~ 
, Pt, _PL . Pt 
4 5 6 
\ 
l leaving 
J group 
,-------a,-- -- --,c,- - -ox~~ ---0- - · 0·0 - - - - - '0" -~ ----~ 
Estrogen 
' ' 
L. - - - - - - - - - - - - - - - - - - - - - - -- - - - - - - - - - -- - - -- - -- - - - - - --- - - ------ -- - - - - -- - - - - - - .J 
As shown in Figure 2.7, the specific target molecule (7) includes a hydrocarbon chain 
that links the steroid to the malonate, which, in turn, coordinates to platinum. 
Figure 2.7 Target Therapeutic Compound 
OH 
0 
HO 
7 0 
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Synthesis of the target platinated estrogen, 7, is designed to consist of two broad 
stages. First, the steroid will be alkylated with an alkyl malonate. Then, following 
appropriate deprotections, platinum will be added. For the first stage, linking compounds 
are required. The general structure for the linking precursors is shown in Figure 2.8. The 
R-groups represent alkyl groups that are needed to protect the carboxyl. The a- methyl 
group should prevent cyclization upon exposure to the carbanion, and the iodide should 
be replaced by the steroid carbanion to afford steroid alkylation. 
Figure 2.8 General Structure of Linkage Molecules 
0 
R =Ami, Bn 
n = 2,4 
Initial research with linkage molecules suggested that the malonate groups 
required protection with highly lipophilic substituents. When estradiol was alkylated 
with linking groups containing methyl protecting groups, chromatographic purification 
and isolation of the alkylated product proved difficult. As a result, the methyl groups 
were replaced with bulkier isoamyl groups to improve chromatographic isolation and 
purification of the alkylated estradiol. 
The family of malonate linkage molecules described in this research began with 
the synthesis of diisoamyl(methyl) malonate, 9, which is shown in Scheme 2.1. The acid-
catalyzed transesterification reaction is used to transform diethyl(methyl) malonate (8) to 
diisoamyl(methyl) malonate 9. 
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Scheme 2.1 Proposed Synthesis of Diisoamyl(methyl) Malonate (9) 
0 
_j-OEt 
~OEt 
0 
8 
+ excess HO~ 0 __To Am; ~OAm' 
0 
9 
• 2 EtOH 
The alkylation of 9 is shown in Schemes 2.2 and 2.3. Because the influence of 
the length of the alkyl chain on therapeutic activity is not known, both a hexyl chain and 
a decyl chain were chosen for evaluation. Sodium hydride should remove the acidic 
malonate proton and generate a carbanion. The controlled addition of the dihalogenated 
alkane should be the final step in alkylation. 
Scheme 2.2 Proposed Synthesis of Diisoamyl-6-iodohexyl(methyl) Malonate (10) 
0 
_FoAm' 
~OAm' 
0 
9 
l(CH,)61 
DMF 
0 
1~--j-oAm' 
/).-oAm' 
0 
10 
(+ Nal) 
Scheme 2.3 Proposed Synthesis ofDiisoamyl-10-iododecyl(methyl) Malonate (11) 
DMF 
0 
I, /'.... /'.... /'-.. /'.... /~OAm' 
'-../ "'-./ yr 'V 'V (+ Nal) 
OAm' 
0 
OAm' ~~~· OAm' 
0 0 
9 11 
Since estradiol contains a base-sensitive phenol and alcohol, these functional 
groups must be protected prior to alkylation. The proposed 7a alkylation of protected 
estradiol is represented in Scheme 2.4. The selective oxidation of estradiol 12 at carbon-
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613 should be achieved to generate ketone 13. The enolate form of 13 can be alkylated 
with alkyl iodides, 14 and it is probable that the enolate will attack the unhindered w-
carbon rather than the iodoester's carbonyl carbons. 15 The alkylation of ketone 13 should 
be selective for carbon-7 because it is the only source of acidic protons. The beta OTHP 
and methyl group should direct the incoming base to deprotonate the alpha position. 
Since the beta position is sterically hindered, the unhindered alpha product should result. 
Thus, ketone 14 should be alkylated at the 7a position. 
Scheme 2.4 Proposed Synthesis of Alkylated Estradiol (14) 
OTHP 1. LIDACOR OTHP OTHP 
1. KO /-amyl 
0 H3C0o(?=J ,_ 0\_oAmi ,,,,,,~~roAmi 
0 0 0 
12 13 14 
The proposed reduction of 14 is represented in Scheme 2.5. Triethylsilane and a 
Lewis acid should selectively reduce the ketone in the presence of the ester since esters 
are known to be stable under these conditions. 16 Removal of the isoamyl groups 
followed by deprotection of the alcohol and phenol should generate a compound ready 
for platinum coordination to become target therapeutic agent 7. 
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Scheme 2.5 Proposed Reduction of Steroidal Ketone 
OTHP 
0 
111 
,_ ~OAmi 
111~0Am1 
0 0 
14 
Et3SiH 
BF3/Et20 
• 
OTHP 
15 
A disadvantage of compound 15 is that three different protection groups must be 
removed. If the protection groups were uniform throughout the molecule, their removal 
would be simpler. Since estradiol can be protected with benzyl groups, 17 
diisoamyl(methyl) malonate could be replaced with dibenzyl(methyl) malonate. 
The synthetic route to dibenzyl(methyl) malonate (17) in outlined in Scheme 2.6. Since 
dibenzyl malonate (16) is commercially available, alkylation with iodomethane should 
yield the desired malonate. 18 
Scheme 2.6 Proposed Synthesis of Dibenzyl(methyl) Malonate (17) 
16 
NaH 
• DMF 
_)-osn 
-----;;-OBn 
0 
17 
Malonate 17 could then be alkylated as shown in Scheme 2. 7. Analogous to the 
alkylation of diisoamyl(methyl) malonate (9), alkylation should be effected with six and 
ten carbon chains. 
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Scheme 2.7 Proposed Synthesis ofDibenzyl-10-iododecyl(methyl) Malonate (18) 
0 
_J-OBn 
~OBn 
0 
17 
NaH l(CH2)10I 
------DMF DMF 
0 
1~'J-OBn 
/~OBn (+ Nal) 
0 
18 
The proposed estrogen with uniform benzyl protecting groups (19) is represented 
in Figure 2.9. The dibenzyl protecting groups on the ester could be removed with 
hydrogenolysis, 19 perhaps at the same time as the benzyl groups on the steroid rings. 
Figure 2.9 Target Compound with Uniform Benzyl Protection (19) 
OBn 
BnO 
19 
0 
0 
OBn 
OBn 
Addition of platinum to the steroidal product is envisioned as a separate project. 
This coordination reaction was not attempted during this research. 
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Chapter II: Section II 
Results and Discussion 
A. Synthesis of diisoamvl(methyl) malonate (9) 
_}-oEt 
~OEt 
0 
8 
Scheme 2.8 Synthesis of Diisoamyl(methyl) Malonate (9) 
+ excess HO~ 0 _)-oAm' )-oAm' 
0 
9 
+ 2 EtOH 
Scheme 2.8 shows the synthesis of diisoamyl(methyl) malonate (9). The boiling 
range of 9 at atmospheric pressure was found to be 136-139 °C, which is higher than the 
boiling points of ethanol (78 °C) and isoamyl alcohol ( 130 °C). Since this boiling range 
is practical for distillation at atmospheric pressure, distillation at reduced pressure was 
not needed. 
As noted earlier, initial difficulties with the chromatographic isolation and 
purification of the akylated estradiol suggested that the malonate groups required 
protection with highly lipophilic substitutents. Previous work with malonate esters found 
that dimethyl(methyl) malonate has an Rrvalue of 0.40 in 9: 1 hexanes/ethyl acetate. 
Replacing the methyl groups with isoamyl groups to synthesize diisoamyl(methyl) 
malonate afforded an Rrvalue of 0.4 7 in 9: 1 hexanes/ethyl acetate, which should ease 
earlier difficulties in chromatographic purification. 
Compound 9 was characterized with TLC, IR (neat), 1H NMR, 13C NMR, and 
LRMS, and all evidence supported the structure given for compound 9 as 
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diisoamyl(methyl) malonate. Microanalysis also confirmed the identity of this 
compound. The spectral data for this compound can be found in the appendix as Figures 
3.4 - 3.7. 
B. Synthesis of diisoamyl-6-iodohexyl(methyl) malonate (10) 
Scheme 2.9 Synthesis of Diisoamyl-6-iodohexyl(methyl) Malonate (10) 
0 
_)-oAm' 
~OAm' 
0 
9 
NaH 
DMF 
]~] 
DMF 
31% 
0 
I, /"'--.. /"--.... ~OAm' 
'-./ ~ ~ /}-oAm' 
0 
10 
(+ Nal) 
Scheme 2.9 shows the synthesis of diisoamyl-6-iodohexyl(methyl) malonate (10). 
Though the above reaction was straightforward and successful, the percent yield was only 
31.01 %. Published results for a similar compound, diethyl-6-bromohexyl(methyl) 
malonate, offered a comparable 41 % yield. 20 
Analysis by thin-layer chromatography (TLC) found starting materials in the 
crude product (see Table 2.1 ), which suggests that increasing the time of the reaction may 
cause an increase in the percent yield. Compound 10 was also analyzed with IR (neat), 
1H NMR, 13C NMR, and LRMS, and all spectral data supported the structure assigned to 
compound 10. Microanalysis also confirmed the identity of the final product. Spectral 
data for this compound can be found in the appendix as Figures 3 .8 - 3 .11. 
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Table 2.1 TLC Analysis for Crude Diisoamyl-6-iodohexyl(methyl) Malonate (10) 
Rr Assignment 
0.00 ? 
0.07 ? 
0.50 diisoamyl(methyl) 
malonate (9) 
0.62 Product (10) 
0.88 diiodohexane 
C. Synthesis of diisoamyl-10-iododecyl(methyl) malonate (11) 
Scheme 2.10 Synthesis of Diisoamyl-10-iododecyl(methyl) Malonate (11) 
0 
_)-oAm' 
~OAm' 
0 
9 
NaH 
DMF DMF 
33% 
0 
1, /"'... ./".._ /"... /"'... /X= OAm i. 
'-../ 'V "V 'V' 'V' (+ Nal) 
OAm' 
0 
11 
The synthesis of 11 is shown in Scheme 2.10. This reaction was similar to the 
synthesis of diisoamyl-6-iodohexyl(methyl) malonate 10, and the percent yield was a 
comparable 33.15%. Once again TLC analysis found starting materials in the crude 
product (see Table 2.2). 
Compound 11 was also analyzed with TLC, IR (neat), 1H NMR, 13C NMR, and 
LRMS, and all spectral data supported the structure assigned to compound 11. 
Microanalysis also confirmed the identity of compound 11. Spectral data for this 
compound can be found in the appendix as figures 3 .12 - 3 .15. 
35 
Table 2.2 TLC Analysis for Crude Diisoamyl-10-iododecyl(methyl) Malonate (11) 
Rr Assignment 
0.00 ? 
0.47 diisoamyl(methyl) 
malonate, 9 
0.66 Product ( 11) 
0.85 diiododecane 
Compounds 9, 10, and 11 are very similar, and the structural changes can be 
followed with the 1H NMR assignments. As shown in Table 2.3, the a-H found at o 3.40 
in the spectrum of diisoamyl(methyl) malonate disappears when the compound is 
alkylated to become compounds 10 and 11. The protons of the a-CH3 are represented as 
a doublet at o 1.39 in compound 9, but as the a-His absent in compounds 10 and 11 the 
protons of the a methyl group appear as a singlet at o 1.35 and o 1.21 respectively. The 
protons adjacent to the halogen in compounds 10 and 11 are correctly represented as a 
triplet with two adjacent protons with constant o values of 3.12. The isoamyl groups do 
not change in the three compounds, and are represented with nearly constant o values 
across all three compounds. 
Table 2.3 1H NMR Proton Assignments for Isoamyl Esters 
Compound aH aCH3 R-CHrl -OCH2R 
9 3.40,q 1.39, d - 4.13, d oft 
10 - 1.35, s 3.12, t 4.10, t 
11 - 1.21, s 3.12, t 4.07, t 
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D. Synthesis of 7o. alkylated estradiol (14) 
Scheme 2.11 Synthesis of 7-a Alkylated Estradiol (14) 
0 
13 
OTHP OTHP 
KO t-amyl BEt3 10 
-------~ --- ------ 0 ,,,,,,,~OAm' 
' 'L /')-oAm' 
0 0 
14 
The synthesis of 14 is shown in Scheme 2.11. Compound 13 was prepared by a 
published procedure. 13 TLC analysis of the crude product from the above reaction found 
seven different compounds, which suggests that the alkylation was not overly selective. 
Compound 14 could not be successfully isolated from the crude oil. The Rr of 14 was 
0.56, and the Rr ofremaining 13 was 0.50. These difficulties suggest that the 7a 
substitutent needs to be more highly lipophilic than compound 10. 
Compound 14 was purified as much as possible with flash chromatography, but 
no yield information was available because purified samples still contained impurities. 
Compound 14 was characterized with 1H NMR and LRMS. LRMS supported the 
structure provided for compound 14, but 1H NMR did not. The spectral data for this 
compound can be found in the appendix as Figures 3 .16 and 3 .17. 
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E. Synthesis of dibenzyl(methyl) malonate (17) 18 
Scheme 2.12 Synthesis of Dibenzyl(methyl) Malonate (17) 
~o~ 0 ~OBc NaH CH~ o/--0 ~ DMF 52% OBn 
0 0 
16 17 
The synthesis of dibenzyl(methyl) malonate (17) is shown in Scheme 2.12. The 
51.5% yield was lower than the published yield of 68.%. 18 Compound 17 was 
characterized with TLC and 1H NMR, and the 1H NMR spectrum matched the published 
spectrum for dibenzyl(methyl) malonate. 18 The 1H NMR spectrum for this compound 
can be found in the appendix of this work as Figure 3.18. 
F. Synthesis of dibenzyl-10-iododecyl(methyl) malonate (18) 
Scheme 2.13 Synthesis of Dibenzyl-10-iododecyl(methyl) Malonate (18) 
_)-osn 
----;;-osn 
0 
17 
~ l(CH2)10l 
DMF 
47% 
I~ OBn 
0 
18 
The synthesis of dibenzyl-10-iododecyl(methyl) malonate (18) is shown in 
Scheme 2.13. The percent yield for this reaction, 46. 8%, was higher than the percent 
yield of similar reactions (see 10 and 11). Unlike the syntheses of 10 and 11, this 
reaction did not result in starting materials in the crude product. 
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Compound 18 was characterized with TLC, IR (neat), 1H NMR, 13C NMR, and 
LRMS, and all spectral data supported the structure assigned to compound 18. 
Microanalysis also confirmed the identity of this compound. Spectral data for 18, can be 
found in the appendix as Figures 3.19, 3.20, 3.21, and 3.22. 
Compounds 17 and 18 are structurally similar, and the structural changes from 17 
to 18 can be monitored with 1H NMR assignments. As outlined in Table 2.4, the a Hin 
compound 17 is not present after alkylation to become compound 18. The a CH3 signal 
changes from a doublet to a singlet. The protons adjacent to the halogen appear as a 
triplet, as in similar alkylated compounds (see Table 2.3). The ten aromatic protons in 
the benzyl group are unaffected by alkylation. 
Table 2.4 1H NMR Proton Assignments for Benzyl Esters 
Compound a H a CH3 R-CHrl Aromatic 
17 3.52, q 1.40, d - 7.31-7.25, m 
18 - 1.45, s 3.18, t 7.33-7.24, m 
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Chapter II: Section III 
Future Research 
Further research could improve the synthesis of the iodo-alkyl malonate esters described 
in this chapter. 
1. The percent yield for the syntheses of 10 and 11 could be improved. As suggested by 
thin-layer chromatography, unreacted starting materials were still present in the crude 
materials. Increasing the reaction time may increase the percent yields above the mid-
30% range. 
2. Just as protected estradiol was alkylated with diisoamyl-6-iodohexyl(methyl) 
malonate (10), similar alkylation should be effected with diisoamyl-10-iododecyl(methyl) 
malonate (11). The protecting groups on the alkylated steroid should then be removed to 
generate alkylated estradiol and prepare for platinum coordination. 
3. The 7a alkylation of ketone 13 was completed, but the percent yield could not be 
determined. This reaction should be repeated so that a percent yield and full 
characterization with microanalysis can be completed. 
4. The use of benzyl protecting groups should be further developed. To determine if 
benzyl groups will offer a substantial advantage over other protecting groups, dibenzyl-
protected estradiol 17 needs to be alkylated with dibenzyl-10-iododecyl(methyl) malonate 
(17) to produce compound 19. The simultaneous removal of the four benzyl groups 
should afford a compound ready for platinum coordination (see Scheme 2.14). 
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Scheme 2.14 Proposed Realization of Uniform Benzyl Protection 
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5. Platinum coordination has not yet been accomplished, and significant effort should be 
committed to accomplishing this final step toward the target molecule 7. 
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Chapter II: Section IV 
Experimental 
Dibenzyl malonate (16), 1, 10-diiododecane, 1,6-diiodohexane, 
isoamyl alcohol (Biotech Grade), methyl iodide, and triethyl borane (IM in THF) were 
obtained from Aldrich Chemical Co. and used as received. Diethyl(methyl) malonate (8) 
and sodium hydride (NaH, 60% in mineral oil) were purchased from Acros Chemical Co. 
and used as received. N,N-Dimethyl formamide (DMF) was obtained from Fisher 
Scientific and distilled from calcium hydride. Ketone (13) was prepared by Diana Davis. 
KOt-Amyl (2.5 Min cyclohexanes) was prepared by Robert Chesnut. Hexanes and ethyl 
acetate were also purchased from Fisher Scientific and used without further purification. 
All water used was deionized, and all flash chromatography was carried out on 200-400 
mesh silica. 
Physical and Analytical Measurements All 1H NMR spectra and 13C NMR 
spectra were obtained on a GE QE-300 MHz FT-NMR spectrometer, and the chemical 
shifts were reported relative to internal solvent reference values of deuterochloroform 
(CDCh) from Aldrich Chemical Co. (for 1H NMR; s, singlet; d, doublet; t, triplet; q, 
quartet; m, multiplet; and non, nonet). Infared spectra were obtained on an Avatar 360 
FT-IR. Thin-layer chromatography (TLC) was performed on Analtech uniplate silica gel 
chromatography plates using various solutions of hexane and ethyl acetate as the eluent, 
and were visualized with iodine, ultraviolet light, or phosphomolybdic acid stain. Low 
Resolution mass spectrometry and elemental analysis were performed at the University of 
Illinois in Urbana, Illinois. 
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Synthesis of diisoamylmethyl malonate (9) Diethylmethyl malonate (8, 5 
mL, 28.99 mmol), isoamyl alcohol (25 mL, 229 mmol), and concentrated sulfuric acid (1 
mL, 18mmol) were combined and heated in a fractional distillation apparatus under 
atmospheric pressure. The temperature rose steadily until distillate collection began at 
68 °C. As distillate was collected, additional isoamyl alcohol (total volume of 
approximately 200 mL) was added to replace the volume transferred to distillate. When 
the temperature reached 130 °C the distillation was stopped, and the solution was 
transferred to an ice bath. The solution was then combined with 100 mL of ethyl acetate, 
and the resulting organic layer was washed with water (100 mL, twice), saturated sodium 
bicarbonate (aq, 100 mL), water (100 mL), and brine (100 mL). Magnesium sulfate was 
added to remove water and then removed via gravity filtration. Solvent removal in vacuo 
afforded a clear, colorless liquid. 
Excess isoamyl alcohol was removed through fractional distillation. Distillation 
fractions with boiling ranges of 78 °C to 85 °C were analyzed by 1 H NMR and found to 
contain only the desired malonate. Yield= 5.6315 g, 75.19%. TLC; Rr = 0.47 in 9: 1 
hexanes/ethyl acetate. IR (Neat): 2959 cm_, (s, C-H), 1736 cm -I (s, C=O), 1752 cm_, 
(s, C=O). 1H NMR (CDCh, 23 °C): 8 4.13 (d oft, J3H-H = 6.91 Hz, J4H-H = 2.53 Hz, 4H, 
OCH£CH2CH(CH3)2), 3.40 (q, JH-H = 7.14 Hz, lH, aH), 1.65 (non, JH-H = 6.74 Hz, 2H, 
OCH2CH2CH(CH3)2), 1.51 (q, JH-1-1 = 6.94 Hz, 4H, OCH2CH2CH(CH3)2), 1.39 (d, JH-H = 
7.26 Hz, 3H, aCH3), 0.90 (d, JH-H = 6.68 Hz, 12H, OCH2CH2CH(CH1)2). 13C NMR 
(CDCh): 8 170.09 (2C), 63.75 (2C), 46.01 (2C), 36.76 (2C), 24.75, 22.20, 13.19 (2C). 
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LRMS (EI): mlz +1=259 (M, 5), 71 (100). Anal. Calcd for C14H260 4 : C, 65.09; H, 
10.14. Found: C, 64.84; H, 10.06. 
Synthesis of diisoamyl-6-iodohexyl(methyl) malonate (10) Following the 
procedure for the synthesis of diisoamyl-10-iododecyl(methyl) malonate (11 ), 
diisoamylmethyl malonate ((9), 6.9010 g, 26.62 mmol) was combined with sodium 
hydride (1.2696 g, 31.74 mmol) and 50 mL ofDMF in an argon environment. The 
enolate solution again developed a light yellow color and a white precipitate. 
An argon environment was established in a second flask charged with 1,6-
diiodohexane (27.8188 g, 82.31 mmol) and 50 mL ofDMF. The enolate solution was 
then added dropwise over ten minutes, and an ice bath was used to maintain the flask at 
room temperature. 
After four hours of stirring at room temperature, the reaction was quenched with 
100 mL of water and a white precipitate formed. The mixture then separated into three 
distinct layers. TLC analysis confirmed that the white precipitate contained no product, 
so it was discarded with the aqueous layer. The remaining organic layer was washed 
with brine (75 mL) and dried over magnesium sulfate. The drying salt was removed by 
gravity filtration, and solvent removal in vacuo afforded a slightly cloudy, yellow oil. 
The final clear, colorless oil was isolated by flash chromatography in 9: 1 
hexanes/ethyl acetate. Yield= 1.8086 g, 31.01 %. TLC: Rr = 0.62 in 9: 1 hexanes/ethyl 
acetate. IR (Neat): 2957 cm -l (s, C-H), 1731 cm -l (s, C=O). 1H NMR (CDCh, 23 °C): 
8 4.10 (t, J 8 _8 = 6.57 Hz, 4H, -OCH2CH2CH(CH3)2), 3.12 (t, JH-H = 6.65 Hz, 2H, R-
CH2I), 1.82-1.56 (m, 6H, -OCH2CH2CH(CH3)2and 2 CH2 groups), 1.48 (q, JH-H = 6.70 
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Hz, 4H, OCH2CH2CH(CH3)2), 1.39-1.34 (m, 6H, 3 CH2 groups), 1.35 (s, 3H, a CH3), 
0.88 (d, JH-H = 6.19 Hz, 12H, -OCH2CH2CH(CH1h). 13C NMR (CDCh): () 172.36 (2C), 
69.60 (2C), 63.71 (2C), 53.58 (2C), 37.03, 35.33, 33.97, 33.28, 30.17, 28.69, 25.80, 
24.82, 24.07, 22.28, 19.74, 16.26, 14.08 (2C), 11.15, 6.99, 6.74. LRMS (EI): m/z + 1 = 
469 (10), 71 (100). Anal. Calcd for C20H37I04 : C, 51.28; H, 7.96. Found: C, 51.10; H, 
8.05. 
Synthesis of diisoamyl-10-iododecyl(methyl) malonate (11) In an argon 
environment, sodium hydride (1.7464 g, 43.66 mmol) was added to freshly-distilled 
DMF (50 mL), and the resulting mixture was stirred as diisoamyl(methyl) malonate ((9), 
9.8102 g, 37.85 mmol) was added over ten minutes. The enolate solution developed a 
light yellow color and a white precipitate. 
A second flask was also placed under an argon environment and charged with 
1,10-diiododecane (45.1849 g, 114.66 mmol) and 50 mL of freshly-distilled DMF. Both 
warming and agitation were required to obtain a homogenous solution. The enolate was 
added dropwise over ten minutes, causing an exothermic reaction. An ice bath was used 
to maintain the temperature of_the resulting mixture at 22 °C. After twenty minutes of 
stirring at room temperature, a white precipitate formed. 
The resulting mixture was stirred for four hours at room temperature, and then 50 
mL of distilled water was added. The resulting organic layer was removed, and the 
aqueous layer was extracted with dichloromethane (100 mL, twice). Pooled organic 
layers were combined and dried over magnesium sulfate. When the drying salt was 
removed via gravity filtration, solvent removal in vacuo afforded a clear, brown oil. 
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The final clear, colorless oil was isolated through flash chromatography in 19: 1 
hexanes/ethyl acetate. Yield= 8.012 g, 40.36%. TLC: Rr= 0.38 in 19:1 hexanes/ethvl 
acetate. IR(Neat): 2927 cm -i (s, C-H), 1732 cm -i (s, C=O). 1H NMR (CDCb, 23 °C): 
8 4.07 (t, JH-H = 6.93 Hz, 4H, -OCH2CH2CH(CH3)2), 3.12 (t, JH-H = 6.95 Hz, 2H, R-
CH2I), 1.803-1.589 (m, 6H, -OCH2CH2CH(CH3)2 and 2 CH2 groups), 1.46 (q, JH-H = 6.60 
Hz, 4H,-OCH2CH2CH(CH3)2), 1.34-1.13 (m, 14H, CH2 groups), 1.21 (s, 3H, a CH3), 
0.86 (d, JH-H = 6.65 Hz, 12H, -OCH2CH2CH(CH1)2). 13C NMR (CDCl3): 8 172.42 (2C), 
69.51(2C), 53.60(2C), 37.02 (2C), 35.40, 33.94, 33.42, 31.48, 30.37, 29.71, 29.30, 29.22, 
28.40, 25.77, 24.80, 24.15, 22.27, 22.31, 19.74, 16.16, 14.05 (2C), 11.09, 7.208. LRMS 
(El): m/z + 1=525 (5), 524 (M, 4), 71 (100). Anal. Calcd for C24H45104 : C, 54.96; H, 
8.65. Found: C, 54.68; H, 8.74. 
Synthesis of 7a-alkylated steroid (14) In an argon environment, a round-bottomed 
flask was charged with 13 (0.1866 g, 3.0933 mmol) and 15 mL ofDME. KOt- amyl (1.4 
mL, 3.584 mmol) was added dropwise as the reaction was stirred, and the solution turned 
light brown. Stirring and warming caused the reaction to become dark brown. After 10 
minutes of stirring, 3 .4 mL (3 .4 mmol) of triethyl borane was added. The resulting 
solution stirred for one hour and lightened to an orange-brown. Diisoamyl-6-
iodohexyl(methyl) malonate (10) was added (1.8086 g dissolved in 2 mL DME), and the 
solution was allowed to stir for another 30 minutes. A second addition of 
KOt-amyl (1.3 mL, 3.328 mmol) was added dropwise and the solution stirred for 35 
minutes. Storage overnight afforded a precipitate. 
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The crude product was extracted with 20 mL of water, 10 mL of diethyl ether, and 
10 mL of brine. The resulting organic layer was collected and dried over magnesium 
sulfate, which was removed with gravity filtration. Solvent removal in vacuo afforded a 
clear oil. 
The final clear, colorless oil was isolated with flash chromatography. Yield 
information was not available. TLC: Rr= 0.64 in 8:2 hexanes/ethyl acetate. 1H NMR 
(CDClJ,23 °C): & 7.06-7.25 (m, Aromatic), 4.10 (t, JH-H = 6.23), 3.76-3.83 (m), 1.23-
1.55 (m), 1.57-2.14 (m), 0.86 (q, JH-H = 5.07). LRMS (EI): mlz = 722 (M-3, 12), 135 
(100). 
Synthesis of dibenzyl(methyl) malonate (17)18 In a round-bottomed flask, sodium 
hydride (0.8008 g, 20 mmol) was combined with 50 mL ofDMF in an argon 
environment. Dibenzyl malonate (16, 5.0 mL, 20 mmol) was then added over ten 
minutes. The resulting solutfon was stirred for thirty minutes at room temperature before 
methyl iodide (1.4 mL, 22 mmol) was added at once. The solution immediately 
developed a cloudy, ecru color. After stirring overnight, the solution had developed a 
white, creamy precipitate covering the inside of the flask, and within this 'shell-like' 
precipitate was a slightly darker tan liquid mixture. 
Both the precipitate and liquid were diluted with 300 mL of ethyl acetate, and the 
resulting organic layer was separated and washed with distilled water (I 00 mL, four 
times) and dried over magnesium sulfate. Suction filtration followed by in vacuo solvent 
removal afforded a light yellow oil. 
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The final clear, colorless oil was isolated via flash chromatography in 9: 1 
hexanes/ethyl acetate. Yield= 3.0702 g, 51.5%. TLC: Rf= 0.40 in 9: 1 hexanes/ethyl 
acetate. A 1H NMR spectrum matched published data18 to confirm the identity of the oil 
as dibenzyl(methyl) malonate. 
Synthesis of dibenzyl-10-iododecyl(methyl) malonate (18) In an argon 
environment, sodium hydride (0.5324 g, 13.31 mmol) was combined with 30 mL ofDMF 
and stirred as dibenzyl(methyl) malonate (17, 3.0702 g, 10.29 mmol) was added over ten 
minutes. The resulting enolate mixture was a cream-colored solution. 
A second flask was charged with 1,10-diiododecane (12.2655 g, 31.12 mmol) and 
30 mL of DMF under argon. The enolate solution was added over ten minutes, and the 
resulting yellow solution stirred at room temperature for 3.5 hours until it was quenched 
by the addition of 50 mL of water. A white precipitate immediately formed, and brine 
was used to control emulsification. The resulting organic layer was removed, and the 
aqueous layer was extracted with dichloromethane (75 mL, twice). Pooled organic layers 
were combined and dried over magnesium sulfate. The drying salt was removed with 
gravity filtration, and solvent removal in vacuo afforded a yellow oil with brown crystals. 
The final clear, colorless oil was isolated with flash chromatography in 9: 1 
hexanes/ethyl acetate. Yield= 2.7196 g, 46.8%. TLC: Rf= 0.52 in 9:1 hexanes/ethyl 
acetate. IR (Neat): 1733 cm-1 (s, C=O). 1H NMR: 8 7.33 - 7.24 (m, lOH, Ar), 5.14 (d, 
JH-H = 12.05 Hz, 2H, benzyl H), 5.09 (d, JH-H = 11.89 Hz, 2H, benzyl H), 3.18 (t, JH-H = 
7.05 Hz, 2H, R CH2I), 1.92-1.77 (m, 4H), 1.45 (s, 3H, a CH3), 1.43-1.10 (m, 14H). 13C 
NMR (CDCh): 8 172.08, 135.57, 128.43, 128.13, 127.95, 66.77, 53.84, 35.52, 31.56, 
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30.46, 29.73, 29.35, 29.23, 28.46, 24.15, 22.63 (2C), 19.84 (2C), 14.1, 7.3. LRMS m/z +l 
= 565 (51), 91 (100). Anal. Calcd for C2sH3704l: C, 59.58; H, 6.61. Found: C, 59.80; H, 
6.65. 
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List of Appendix Figures 
Figure 3.1 300 MHz 1H NMR of THP-protected 2-bromophenol (17) 
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Figure 3.7 IR of diisoamyl(methyl) malonate (9) 
Figure 3.8 300 MHz 1H NMR of diisoamyl-6-iodohexyl(methyl) malonate (10) 
Figure 3.9 300 MHz 13C NMR of diisoamyl-6-iodohexyl(methyl) malonate (10) 
Figure 3.10 LRMS of diisoamyl-6-iodohexyl(methyl) malonate (10) 
Figure 3 .11 · IR of diisoamyl-6-iodohexyl(methyl) malonate (10) 
Figure 3.12 300 MHz 1H NMR of diisoamyl-10-iododecyl(methyl) malonate (11) 
Figure 3.13 
Figure 3.14 
Figure 3.15 
Figure 3.16 
Figure 3.17 
Figure 3.18 
Figure 3.19 
Figure 3.20 
300 MHz 13C NMR of diisoamyl-10-iododecyl(methyl) malonate (11) 
LRMS of diisoamyl-10-iododecyl(methyl) malonate (11) 
IR of diisoamyl-10-iododecyl(methyl) malonate (11) 
300 MHz 1H NMR of Product of Alkylation Attempt (14) 
LRMS of Product of Alkylation Attempt (14) 
300 MHz 1H NMR of dibenzyl(methyl) malonate (17) 
300 MHz 1H NMR of dibenzyl-10-iododecyl(methyl) malonate (18) 
300 MHz 13C NMR of dibenzyl-10-iododecyl(methyl) malonate (18) 
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Figure 3.21 LRMS of dibenzyl-10-iododecyl(methyl) malonate (18) 
Figure 3.22 IR of dibenzyl-10-iododecyl(methyl) malonate (18) 
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ffi-IODOALKYL(METHYL)MALONATE ESTERS 
Sara E. Bendler, Jason S. Bundy, Sarah A. Clark, Diana N. Davis, Nicole A. Orwar, Robert W. 
Chesnut*, Department of Chemistry, Eastern Illinois University, 600 Lincoln Ave. Charleston, 
IL 61920. 
ffi-lodoalkyl(methyl)malonate esters have potential utility in the bioconjugate chemistry of 
steroids. A representative set of these esters with a variety of protecting groups and alkyl groups 
has been prepared. The compounds offer a range of elution values on silica, as well as several 
convenient deprotection options. 
ffi-Bromoalkyl(methyl)malonate esters are precursors of chalcogenobarbiturates, which, in 
radiolabeled form, may be useful as brain imaging agents.(1) Recently, we have become 
interested in the analogous ffi-iodoalkyl(methyl)malonate esters because of their possible utility 
in the bioconjugate chemistry of steroids. It is known that steroids can be conjugated to platinum 
through a malonate moiety.(2) Such platinated steroids are significant because of their potential 
as tissue-selective antitumor agents. 
76 
We have synthesized the versatile set of c.o-iodoalkyl(methyl)malonate esters shown in Table 1. 
The labile iodide offers a means of substituting steroid-derived nucleophiles, while the malonate 
ester can be deprotected to afford a metal-chelating ligand. We have included both six-carbon 
and ten-carbon chains, since both have been employed in steroid conjugates.(3 - 5) 
Compound n R 
0 la 6 -CH3 I(CH2)o~OR 
H3C OR lb 10 -CH3 
0 
2a 6 -CH2CH2CH(CH3)z 
2b 10 -CH2CH2CH(CH3)2 
3 10 -CH2Ph 
Table 1. c.o-Iodoalkyl(methyl)malonates 
While compounds 1 and 2 all include simple alkyl protecting groups, there is a practical 
difference between any two compounds with the same value ofn. In a given chromatographic 
solvent, an isoamyl group causes much more rapid elution on silica than is possible for the 
analogous methyl ester. We have found that this difference in chromatographic behavior extends 
to steroidal compounds that have been alkylated with compounds 1 and 2. Thus, ease of 
purification of the alkylated product can be maximized by the choice of 1 or 2 as an alkylating 
agent. In its chromatographic behavior, compound 3 is similar to 1 b. 
77 
Compounds 1 - 3 offer a range of deprotection options, including acid-catalyzed hydrolysis or 
base-catalyzed hydrolysis; compound 3 can be deprotected by hydrogenolysis. Assessment of 
deprotection reactions is simple, since all of the protecting groups have distinctive 1H NMR 
resonances that are convenient to monitor. 
EXPERIMENTAL 
Except in the synthesis of diisoamyl(methyl)malonate, all synthetic operations were carried out 
under Argon. NaH, dimethyl(methyl)malonate, diethyl(methyl)malonate, dibenzyl malonate, 
methyl iodide, 1,6-diiodohexane, 1, 10-diiododecane, and isoamyl alcohol were purchased from 
Aldrich, and were used as received. Dimethylformamide (DMF) was distilled from CaH2 and 
stored over molecular sieves. Dibenzyl(methyl)malonate was prepared by a published 
procedure.(6) Silica GF from Analtech was used as the solid for all TLC; staining was done with 
iodine. Flash chromatography was conducted with silica gel, Merck grade 9385, 230- 400 mesh, 
40A. NMR spectra were collected in CDCb on a QE 300 instrument. Mass spectra (low-
resolution, electron-impact ionization) were obtained on a VSE-70 instrument at the School of 
Chemical Sciences, University of Illinois at Urbana-Champaign. Elemental analyses were 
conducted by the Microanalytical Laboratory at the School of Chemical Sciences, University of 
Illinois at Urbana-Champaign. 
Diisoamyl(methyl)malonate 
78 
A solution of diethylmethylmalonate (5 mL, 28.99 mmol), isoamyl alcohol (25 mL, 229.44 
mmol), and concentrated sulfuric acid (1 mL, 18 mmol) was heated to boiling. Ethanol was 
continuously collected by distillation, and isoamyl alcohol was added to maintain the volume of 
the solution. Boiling continued until the vapor temperature rose to 130°C and analysis by TLC 
indicated complete conversion of diethylmethylmalonate. The solution was cooled and diluted 
with 100 mL of ethyl acetate. Following washes with water, aqueous NaHC03, water, and brine, 
the solution was dried over MgS04• Ethyl acetate was removed on a rotary evaporator, then the 
residue was fractionally distilled at reduced pressure (1.5 mm Hg). Colorless liquid that distilled 
at 78 °C to 85 °C was collected. Yield: 5.63 g (75.2%). Rr = 0.47 in 9:1 hexane/ethyl acetate. IR 
(Neat): 1736 cm-1 (s, C=O). 1H NMR: 8 4.13 (d oft, J1 = 6.91Hz,Ji=2.53 Hz, 4H,), 3.40 (q, J = 
7.14 Hz, lH), 1.65 (non, J = 6.74 Hz, 2H), 1.51(q,J=6.94 Hz, 4H), 1.39 (d, J = 7.26 Hz, 3H), 
0.90 (d, J = 6.68 Hz, 12H). 13C NMR (CDCh): D 170.09, 63.75, 46.01, 36.76, 24.75, 22.20, 
13.19. 259 (M, 5), 71 (100). Anal. Calcd for C14H2604 : C, 65.09; H, 10.14. Found: C, 64.84; H, 
10.06. 
Dimethyl 6-iodohexyl(methyl)malonate 
A mixture of2.28 g (57.1 mmol) of 60% NaH in mineral oil and 25 mL ofDMF was stirred as 
7.36 g (50.4 mmol) of dimethylmethyl malonate was added over 10 minutes. The resulting 
mixture was transferred to an addition funnel and added over 20 minutes to 33.83 g (100.1 
mmol) of stirred 1,6-diiodohexane. After 25 minutes of stirring, the mixture was poured into 75 
mL of water, and 60 mL of chloroform was added. The organic layer was removed, and the 
79 
aqueous layer was extracted with an additional 30 mL of chloroform. The pooled chloroform 
extracts were washed with 100 mL of brine and dried over MgS04. Removal of solvent in vacuo 
afforded a crude product that was purified by flash chromatography (Rr = 0.40 in 9: 1 
hexane/ethyl acetate). Yield of colorless oil: 6.90 g (38.4%). IR (neat): 1734 cm-1 (s, C=O). 1H 
NMR: o 3.64 (s, 6H), 3.10 (t, J = 7.0 Hz, 2H), 1.80-1.69 (m, 4H), 1.33 (s, 3H), 1.30-1.10 (m, 
6H). 13C NMR o: 172.60, 53.43, 52.28, 35.36, 33.18, 30.03, 28.53, 23.94, 19.81, 6.89 ppm. MS 
(m/z) (rel. intensity): 356.1 (M, 3.7), 146.1 (100). Anal. Calcd for C12H21 0 4I: C, 40.46; H, 5.94. 
Found C, 40.69; H, 5.99% 
Dimethyl 10-iododecyl(methyl)malonate 
A mixture of2.28 g (57.1 mmol) of60% NaH in mineral oil and 25 mL ofDMF was stirred as 
7.36 g (50.4 mmol) of dimethyl( methyl) malonate was added over 10 minutes. The resulting 
mixture was transferred to an addition funnel and added over 10 minutes to a stirred solution of 
39.40 g (100.0 mmol) of 1,10-diiododecane in 30 mL ofDMF. A white precipitate formed. The 
workup was identical to that used for dimethyl 6-iodohexyl(methyl) malonate. The product was 
purified by flash chromatography (Rr = 0.50 in 9: 1 hexane/ethyl acetate). Yield of colorless oil: 
9.36 g (52.1 %). IR (neat): 1735 cm-1 (s, C=O). 1H NMR: o 3.66 (s, 6H), 3.14 (t, J = 7.2 Hz, 2H), 
1.82 - 1.72 (m, 4H), 1.35 (s, 3H), 1.28 - 1.20 (m, 14H). 13C NMR o: 172.84, 76.58, 53.59, 
52.34, 35.55, 33.44, 30.38, 29.69, 29.30, 29.27, 29.18, 28.42, 24.17, 19.88, 7.31. MS (m/z) (rel. 
intensity): 412.1(M,0.76%), 146.1 (100). Anal. Calcd for C16H2904l: C, 46.61; H, 7.09. Found 
C, 46.50; H, 7.34%. 
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Diisoamyl 6-iodohexyl(methyl)malonate 
A mixture of 1.27 g (31. 7 mmol) of 60% NaH in mineral oil and 50 mL of DMF was stirred as 
6.91 g (26.6 mmol) of diisoamyl(methyl) malonate was added over 10 minutes. The resulting 
mixture was transferred to an addition funnel and added over 10 minutes to a stirred solution of 
27.8 g (82.3 mmol) of 1,6-diiodohexane in 50 mL ofDMF. During addition, an ice bath was 
used as needed to maintain the temperature at 22 °C. The mixture was stirred for four hours at 
room temperature, then 50 mL of distilled water was added. The organic layer was removed, and 
the aqueous layer was extracted with CH2Ch (100 mL, twice). The pooled organic layers were 
combined and dried over MgS04• Removal of solvent removal in vacuo afforded an oil that was 
purified by flash chromatography (Rr = 0.62 in 9: 1 hexane/ethyl acetate). Yield of colorless oil: 
1.81 g (31.0 %). IR (Neat): 1731 cm-1 (s, C=O). 1H NMR: o 4.10 (t, J = 6.57 Hz, 4H), J = 6.65 
Hz, 2H), 1.82-1.56 (m, 6H), 1.48 (q, J = 6.70 Hz, 4H), 1.39-1.34 (m, 6H), 1.35 (s, 3H), 0.88 (d, J 
= 6.19 Hz, 12H). 13C NMR (CDCb): 0 172.36, 69.60, 63.71, 53.58, 37.03, 35.33, 33.97, 33.28, 
30.17, 28.69, 25.80, 24.82, 24.07, 22.28, 19.74, 16.26, 14.08, 11.15, 6.99, 6.74. MS (m/z) (rel. 
intensity): 469 (M, 10), 468 (M, 10), 71 (100). Anal. Calcd for C20H37I04 : C, 51.28; H, 7.96. 
Found: C, 51.10; H, 8.05. 
Diisoamyl 10-iododecyl(methyl)malonate 
A mixture of 1.74 g (43.7 mmol) of 60% NaH in mineral oil and 50 mL ofDMF was stirred as 
9.81 g (37.9 mmol) of diisoamyl(methyl) malonate was added over 10 minutes. The resulting 
mixture was transferred to an addition funnel and added over 10 minutes to a stirred solution of 
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45.2 g (115 mmol) of 1,10-diiododecane in 50 mL ofDMF. During addition, an ice bath was 
used as needed to maintain the temperature at 22 °C. The mixture was stirred for four hours at 
room temperature. The workup was identical to that used for diisoamyl 6-iodohexyl(methyl) 
malonate. Removal of solvent in vacuo afforded a brown oil and a precipitate. The oil was 
purified by flash chromatography (Rr= 0.38 in 19:1 hexane/ethyl acetate). Yield of colorless oil: 
8.01 g (40.4 %). IR (Neat): 1732 cm-1 (s, C=O). 1H NMR: 8 4.07 (t, J = 6.93 Hz, 4H), 3.12 (t, J 
= 6.95 Hz, 2H), 1.803-1.589 (m, 6H), 1.46 (q, J = 6.60 Hz, 4H), 1.34-1.13 (m, 14H), 1.21 (s, 
3H), 0.86 (d, J = 6.65 Hz, 12H). 13C NMR (CDCh): 0 172.42, 69.51, 53.60, 37.02, 35.40, 33.94, 
33.42, 31.48, 30.37, 29.71, 29.30, 29.22, 28.40, 25.77, 24.80, 24.15, 22.27, 22.31, 19.74, 16.16, 
14.05, 11.09, 7.208. MS (m/z) (rel. intensity): m/z 525 (M, 5), 524 (M, 4), 71 (100). Anal. Calcd 
for C24H45I04 : C, 54.96; H, 8.65. Found: C, 54.68; H, 8.74. 
Dibenzyl 10-iododecyl( methyl)malonate 
A mixture of0.532 g (13.3 mmol) of 60% NaH in mineral oil and 30 mL ofDMF was stirred as 
3.07 g (10.3 mmol) of dibenzyl(methyl) malonate was added over 10 minutes. The resulting 
solution was transferred to an addition funnel and added over 10 minutes to a stirred solution of 
12.3 g (31.1 mmol) of 1,10-diiododecane in 30 mL ofDMF. The yellow solution that formed 
was stirred for 3.5 hours. The workup was identical to that used for diisoamyl 6-
iodohexyl(methyl) malonate. Removal of solvent in vacuo afforded an oil and a brown 
precipitate. The oil was purified by flash chromatography (Rr = 0.52 in 9: 1 hexane/ethyl acetate). 
Yield of colorless oil that solidified at -4 C0 : 2. 72 g ( 46.8 %). IR (Neat): 1733 cm-1 (s, C=O). 
1H NMR: 8 7.33 - 7.24 (m, lOH), 5.14 (d, J = 12.05 Hz, 2H), 5.09 (d, J = 11.89 Hz, 2H), 3.18 (t, 
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J = 7.05 Hz, 2H), 1.92-1.77 (m, 4H), 1.45 (s, 3H), 1.43-1.10 (m, 14H). 13C NMR (CDCh): o 
172.08, 135.57, 128.43, 128.13, 127.95, 66. 77, 53.84, 35.52, 34.63, 33.49, 31.56, 30.46, 29.73, 
29.32, 28.46, 24.15, 22.63, 19.84, 14.1, 7.3. MS (m/z) (rel. intensity): 565 (M, 51), 91 (100). 
Anal. Calcd for C28H370 4I: C, 59.58; H, 6.61. Found: C, 59.80; H, 6.65. 
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